drug
Xarelto
Marketedupdated 6mo agoby Johnson & Johnson Innovative Medicine
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 4all catalysts(0)
nothing on the calendar yet
Trials studying Xarelto
- phase3Reducing Adverse Vascular Outcomes With Factor XI Inhibition in Adult Participants With Peripheral Artery Disease
- phase3Comparison of Anti-coagulation and Anti-Platelet Therapies for Intracranial Vascular Atherostenosis
- phase1Single Dose Trial of VMX-C001 in Healthy Subjects With and Without FXa Direct Oral Anticoagulant
- N/ADEFIANCE: RCT of ClotTriever System Versus Anticoagulation In Deep Vein Thrombosis
- —A Study to Observe the Pattern of Use and Safety of Rivaroxaban in Children Under 2 Years Old With Venous Thromboembolism (VTE)
- —An Observational Study to Learn More About How Safe Treatment With Rivaroxaban is in Children in Japan With Venous Thromboembolism
- N/APill-in-the-POCKET Oral Anticoagulation Strategy After AF Catheter Ablation
- phase1A Study to Investigate Andexanet Dosing and the Interaction Between Andexanet and Subsequent Enoxaparin in Healthy Participants
News(3)
- Bayer wins first-in-class FDA nod for blood thinner, setting stage for BMS-J&J rivalBayer’s Sunharbo has secured the first FDA approval of its class, establishing a regulatory pathway for other factor XIa inhibitors, such as Bristol Myers Squibb and Johnson and Johnson’s milvexian.biospace · 6d ago
- Bayer wins FDA nod for a new kind of blood thinnerSunharbo’s U.S. approval is the first for a “Factor XIa” inhibitor, an anticipated class of medicines seen as a possible step forward in stroke prevention.biopharma_dive · 7d ago
- 10 clinical trials to watch in the second half of 2026The biotechnology sector’s upswing accelerated in the first half. Positive results from anticipated trials in lung cancer, Alzheimer’s and multiple autoimmune conditions could add to the momentum.biopharma_dive · 4mo ago
Data sources
last refreshed 27m ago
Found something off?
comments(0)
5-min edit window · permanent after that